RenovoRx (RNXT) AI Stock Analysis

• Market Cap: $35.35M
• Dividend Yield: N/A
• Average Volume (3M): 288.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: 37.89%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 36,649,918
• 10 Day Avg. Volume: 236,040
• 30 Day Avg. Volume: 288,821
• PEG Ratio: 0.13
• Price to Book (P/B): 6.80
• Price to Sales (P/S): 708.18
• P/FCF Ratio: -3.33
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 28.21
• Enterprise Value/Gross Profit: 41.62
• Enterprise Value/Ebitda: -3.27
• 1Y Price Target: $6.10
• Price Target Upside: 535.42% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $0.97 ▲(0.52% Upside)

The score is held back primarily by weak financial performance—large operating losses and substantial cash burn despite improving revenue and a low-debt balance sheet. Technicals are comparatively supportive with the stock above major moving averages and positive MACD, while valuation is constrained by negative earnings. The latest earnings call was broadly positive on commercial expansion and trial progress, but this is partially offset by the Nasdaq bid-price compliance risk.

Positive Factors

Low leverage and improved balance sheet

Very low debt and a materially improved equity base reduce refinancing and solvency risk over the next 2–6 months. This stronger capitalization improves flexibility to fund clinical and commercial programs without immediate reliance on high-cost borrowing, supporting durable operational continuity.

Early revenue growth with high gross margin

Meaningful top-line growth from a small base combined with a ~62.8% gross margin suggests the product/delivery model can scale with attractive unit economics. If commercial momentum continues, high gross margins provide a persistent lever to improve operating leverage as fixed costs are absorbed.

Commercial traction and expanding clinical adoption

Steady expansion across academic and community centers indicates growing clinical adoption and a repeatable sales process. Institutional approvals and repeat physician use support sustainable market penetration and create a structural pathway to scale RenovoCath and TAMP therapy over multiple years.

Negative Factors

Persistent heavy cash burn

Sustained negative operating and free cash flow of roughly $10M TTM is a structural constraint that will necessitate additional financing or material operational scaling to avoid dilution. This persistent burn reduces runway and limits strategic optionality absent revenue acceleration.

Large operating and net losses

Significant operating deficits relative to revenue imply the business remains far from break-even. Continued high negative margins pressure return prospects and require sustained commercial scale or cost restructuring to achieve durable profitability over the medium term.

Nasdaq bid-price deficiency and listing risk

Formal Nasdaq noncompliance introduces structural governance and financing risk: management may need dilutive financings or a reverse split to retain the listing. Listing uncertainty can impede access to equity markets and institutional investors over the medium term.

RenovoRx Business Overview & Revenue Model

Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

How the Company Makes Money

RenovoRx generates revenue primarily through the development and commercialization of its RenovoTAMP therapy platform. The company aims to monetize its technology through licensing agreements with pharmaceutical companies and healthcare institutions. Additionally, RenovoRx seeks to establish partnerships and collaborations to further develop its therapeutic applications, which can lead to milestone payments and royalties. The company's financial strategy may also include seeking funding through public and private investments to support ongoing research and development efforts.

RenovoRx Financial Statement Overview

Summary

Revenue is growing off a small base (TTM ~$0.93M, +40.2%) with positive gross margin (~62.8%), and leverage is low (debt ~$0.24M; debt-to-equity ~0.02). However, operating and net losses remain very large (EBIT about -$11.6M; net income about -$11.1M) and cash burn is heavy (operating and free cash flow about -$10.4M), making funding needs a key risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue increased sharply (+40.2%) to ~$0.93M, and gross profit was positive with a solid ~62.8% gross margin. However, profitability remains very weak: operating losses are large (EBIT of about -$11.6M) and net losses are significant (net income about -$11.1M), resulting in deeply negative margins. Overall, the company shows early revenue traction, but losses remain outsized relative to the current revenue base.

Balance Sheet

Leverage is low, with TTM (Trailing-Twelve-Months) total debt of ~$0.24M and a modest debt-to-equity ratio (~0.02), which reduces financial risk. Equity and assets improved versus 2024 (equity ~$8.1M vs. ~$4.5M; assets ~$11.2M vs. ~$8.1M), indicating balance sheet rebuilding. The main weakness is returns: profitability is negative and return on equity remains very poor, reflecting ongoing losses despite improved capitalization.

Cash Flow

Cash generation remains a key pressure point: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow were both about -$10.4M, indicating continued cash burn to fund operations. While free cash flow growth appears positive in the latest period, the business is still meaningfully cash-flow negative and will likely require sustained funding unless revenue scales materially or spending is reduced.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	928.00K	43.00K	0.00	0.00	0.00	0.00
Gross Profit	629.00K	43.00K	0.00	0.00	0.00	0.00
EBITDA	-8.01M	-10.97M	-11.39M	-9.94M	-5.48M	0.00
Net Income	-11.11M	-8.81M	-10.23M	-9.89M	-6.32M	-3.80M
Balance Sheet
Total Assets	11.21M	8.12M	1.47M	7.26M	16.29M	1.91M
Cash, Cash Equivalents and Short-Term Investments	10.04M	7.15M	1.17M	6.44M	15.19M	1.79M
Total Debt	236.00K	278.00K	0.00	0.00	0.00	2.79M
Total Liabilities	3.13M	3.64M	4.47M	1.10M	938.00K	16.57M
Stockholders Equity	8.08M	4.48M	-3.00M	6.16M	15.35M	-14.66M
Cash Flow
Free Cash Flow	-10.40M	-9.14M	-10.26M	-8.81M	-5.93M	-3.53M
Operating Cash Flow	-10.38M	-9.13M	-10.26M	-8.81M	-5.92M	-3.53M
Investing Cash Flow	-14.00K	-12.00K	2.03M	-2.03M	-15.00K	0.00
Financing Cash Flow	10.88M	15.12M	5.01M	42.00K	19.33M	3.20M

RenovoRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.96
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Negative. The current price of 0.96 is below the 20-day moving average (MA) of 1.02, above the 50-day MA of 0.94, and below the 200-day MA of 1.11, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 60.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNXT.

RenovoRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRCE	58 Neutral	$56.94M	-6.29	-13.15%	―	―	45.97%
JSPR	52 Neutral	$38.62M	-0.23	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNXT	51 Neutral	$35.35M	-2.71	-146.61%	―	―	37.89%
OVID	47 Neutral	$192.67M	-2.90	-60.06%	―	946.61%	-11.30%
PEPG	47 Neutral	$337.55M	-1.73	-62.25%	―	―	4.71%
NRSN	44 Neutral	$26.67M	-1.54	―	―	―	31.09%

RenovoRx Corporate Events

RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance

On December 31, 2025, RenovoRx, Inc. received a deficiency notice from Nasdaq stating that the company’s common stock had failed to meet the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market for 32 consecutive business days, although the notice did not immediately affect the stock’s listing status. The company has been granted an initial 180-day period, until June 30, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days, with the possibility of an additional 180-day extension if it meets other listing standards and commits to corrective actions such as a potential reverse stock split; failure to comply after these periods could lead to delisting proceedings, though the company would have the right to appeal.

The most recent analyst rating on (RNXT) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.

RenovoRx Enters Capital on Demand Sales Agreement

On November 14, 2025, RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to issue and sell up to $3,723,029 in shares of its common stock. This agreement, which involves at-the-market offerings or negotiated transactions, is part of RenovoRx’s strategy to leverage its shelf registration statement, extending its ability to raise capital and potentially impacting its market positioning by enhancing financial flexibility.

The most recent analyst rating on (RNXT) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.

RenovoRx Expands Reach with RenovoCath Approval

RenovoRx reported its third-quarter 2025 financial results, highlighting approximately $900,000 in year-to-date revenue and a cash position of $10 million. The company is expanding its commercial reach with the RenovoCath device, now approved in 14 cancer centers, and is advancing its Phase III TIGeR-PaC trial, with enrollment completion expected in early 2026. The company aims to leverage its TAMP platform for long-term growth and improve patient outcomes with targeted therapies.

The most recent analyst rating on (RNXT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.